Kardiovaskuläre Risiken der Androgendeprivationstherapie beim Prostatakarzinom-Reference-Cited by-同舟云学术

Kardiovaskuläre Risiken der Androgendeprivationstherapie beim Prostatakarzinom

Published:2016-03-22 Issue:5 Volume:55 Page:627-631
ISSN:0340-2592
Container-title:Der Urologe
language:de
Short-container-title:Urologe

Author:

Miller K.

Publisher

Springer Science and Business Media LLC

Subject

Urology

Link

http://link.springer.com/content/pdf/10.1007/s00120-015-0021-1.pdf

Reference29 articles.

1. Mason M (2006) What implications do the tolerability profiles of antiandrogens and other commonly used prostate cancer treatments have on patient care. J Cancer Res Clin Oncol 132:27–35

2. AWMF/DKG/DeutscheKrebshilfe (2914) Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms

3. Seidenfeld J, Samson DJ, Hasselblad V et al (2000) Single-therapy androgen suppression in men with advanced prostate cancer. A systematic review and meta-analysis. Ann Intern Med 132:566–577

4. Klotz L, Boccon-Gibod L, Shore ND et al (2008) The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. Br J Urol Int 102:1531–1538

5. D’Amico AV, Denham JW, Crook J et al (2007) Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 25:2420–2425

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Androgen-Deprivation Therapy and Cardiovascular Disease Risk – The Role of Exercise in Prostate Cancer Treatment;Frontiers in Oncology;2016-09-19